- NeuroOne Medical Technologies Corporation NMTC has executed an agreement with RBC Medical Innovations for a proprietary radiofrequency (RF) generator.
- The program will develop and manufacture an RF generator for use with NeuroOne's ablation electrode designed to record brain activity and ablate brain tissue using the same electrode.
- Currently, two separate hospital visits and surgeries are required to treat seizures due to epilepsy or brain tumors that contribute to seizures.
- The partnership will offer a complete system combining the ablation electrode with the hardware and software required to perform the procedures.
- The project is expected to be completed in late 2022, pending receipt of regulatory clearance.
- Price Action: NMTC shares are up 8.39% at $4.20 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
